EP3331571A4 - COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS - Google Patents

COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS Download PDF

Info

Publication number
EP3331571A4
EP3331571A4 EP16804107.7A EP16804107A EP3331571A4 EP 3331571 A4 EP3331571 A4 EP 3331571A4 EP 16804107 A EP16804107 A EP 16804107A EP 3331571 A4 EP3331571 A4 EP 3331571A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
viral infections
treating viral
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16804107.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3331571A1 (en
Inventor
Stephen R. Quake
Jianbin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenovir Corp
Original Assignee
Agenovir Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenovir Corp filed Critical Agenovir Corp
Publication of EP3331571A1 publication Critical patent/EP3331571A1/en
Publication of EP3331571A4 publication Critical patent/EP3331571A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP16804107.7A 2015-05-29 2016-05-27 COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS Withdrawn EP3331571A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168259P 2015-05-29 2015-05-29
US201562168262P 2015-05-29 2015-05-29
PCT/US2016/034606 WO2016196273A1 (en) 2015-05-29 2016-05-27 Compositions and methods to treat viral infections

Publications (2)

Publication Number Publication Date
EP3331571A1 EP3331571A1 (en) 2018-06-13
EP3331571A4 true EP3331571A4 (en) 2019-04-10

Family

ID=57441664

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16804107.7A Withdrawn EP3331571A4 (en) 2015-05-29 2016-05-27 COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS

Country Status (4)

Country Link
EP (1) EP3331571A4 (enExample)
JP (1) JP2018516983A (enExample)
CA (1) CA3000189A1 (enExample)
WO (1) WO2016196273A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3324999A1 (en) * 2015-05-29 2018-05-30 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4179085A1 (en) * 2020-07-07 2023-05-17 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
EP4281184A4 (en) * 2021-01-25 2025-04-30 Fred Hutchinson Cancer Center TREATMENT OF HSV-1 USING A MEGANUCLEASE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016196273A1 *
YANWEI BI ET AL: "High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases", PLOS PATHOGENS, vol. 10, no. 5, 1 May 2014 (2014-05-01), pages e1004090, XP055198358, DOI: 10.1371/journal.ppat.1004090 *

Also Published As

Publication number Publication date
JP2018516983A (ja) 2018-06-28
CA3000189A1 (en) 2016-12-08
EP3331571A1 (en) 2018-06-13
WO2016196273A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EP3471745A4 (en) METHOD AND COMPOSITIONS FOR REDUCING OXIDATIVE STRESS
EP3493827A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
MA52506A (fr) Procédés de traitement d'infections par des virus nipah
EP3405577A4 (en) COMPOSITIONS AND METHOD FOR INHIBITING THE FACTOR D
MA43283A (fr) Procédés et compositions pour le traitement du cancer
ZA201706681B (en) Compositions and methods for treating anemia
EP3319976A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LUNG DISEASES AND LUNG LESIONS
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
EP3334358A4 (en) ELECTRO-SURGICAL GENERATOR AND METHOD
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP2947990A4 (en) COMPOSITIONS AND METHODS FOR PEST CONTROL
EP3307296A4 (en) METHOD AND COMPOSITIONS FOR TREATING AGE-SATISFIED SUFFERING
IL262579A (en) Compounds and methods for treating viral infection in shrimp
EP3389657A4 (en) METHOD FOR THE TREATMENT OF HYPERALGESIA
EP3380095A4 (en) COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC STROKE
EP3512524A4 (en) METHOD AND COMPOSITIONS FOR TREATING VIRUS INFECTIONS
EP3298151A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING THE PH VALUE
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3402575A4 (en) METHOD AND COMPOSITIONS FOR TREATING DAMAGED HAIR
IL291266A (en) Preparations and methods for treating infections
EP3317290A4 (en) COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION
EP3429690A4 (en) METHOD FOR MODULATING KEAP1
EP3386593A4 (en) IMMUNOMODULATING COMPOSITION FOR TREATMENT
EP3359553A4 (en) COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENOVIR CORPORATION

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20190304BHEP

Ipc: A61K 9/08 20060101ALI20190304BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255580

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191008

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1255580

Country of ref document: HK